GDP方案治疗复发性或难治性非霍奇金淋巴瘤临床分析

目的:观察GDP方案(GEM+DDP+DXM)治疗复发性或难治性非霍奇金淋巴瘤的疗效和不良反应。方法:2008年1月至2010年3月安徽医科大学附属六安医院肿瘤中心收治的23例复发性或难治性非霍奇金淋巴瘤患者,给予吉西他滨(GEM)1000 mg/m2静脉滴注,d1,8;顺铂(DDP)25mg/m2静脉滴注,d1-3;地塞米松(DXM)20-40mg静脉滴注,d1-3,21天为1周期,2个周期后评价疗效,并随访疾病进展情况。结果:23例患者中,14例缓解(60.9%),其中完全缓解5例(21.7%),部分缓解9例(39.1%)。23例患者中位肿瘤进展时间(TTP)为5.0个月(95%CI:3-8个月)。主要不良反应为骨髓抑制和轻中度消化道反应。骨髓抑制表现为3-4级白细胞减少2例;3-4级血红蛋白减少1例;3-4级血小板减少1例,并发出血。结论:GDP方案治疗复发性或难治性非霍奇金淋巴瘤是一个有效,相对不良反应较轻的二线挽救方案。

Efficacy of GDP regimen on relapsed or refractory non-Hodgkin's lymphoma

Objective:To evaluate the efficacy and side effects of chemotherapy with GDP regimen in patients with relapsed or refractory Non-Hodgkin’s lymphoma. Methods: Twenty-three patients with relapsed or refractory non-Hodgkin’s lymphoma were enrolled from January 2008 to March 2010. They received gemcitabine 1000mg/m2 ,d1,d8 and cisplatin 25mg/m2,d1-d3, in combination with dexamethasone 20-40mg d1-d3 every 21 days. Efficacy assessment was conducted after two cycles therapy. Results: Among 23 patients,5 cases achieved complete response (21.7%) and 9 cases achieved partial response (39.1%).The median time to progression (TTP) was 5 months (95%CI:3-8 months).The major adverse events were mild to moderate gastrointestinal reaction and myelosuppression which included 2 cases of grade 3-4 leukopenia and 1case of grade 4 thrombopenia with hemorrhage and 1 case of grade 3-4 hemophthisis. Conclusion: GDP regimen is effective and well-tolerated for relapsed or refractory non-Hodgkin’s lymphoma.